JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Keats, A. S.
Right arrow Articles by Telford, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keats, A. S.
Right arrow Articles by Telford, J.
Journal of Pharmacology And Experimental Therapeutics, Vol. 143, Issue 2, 157-164, 1964
Copyright © 1964 by American Society for Pharmacology and Experimental Therapeutics


STUDIES OF ANALGESIC DRUGS. VIII. A NARCOTIC ANTAGONIST ANALGESIC WITHOUT PSYCHOTOMIMETIC EFFECTS

Arthur S. Keats 1 and Jane Telford 1

1 Division of Anesthesiology, Baylor University College of Medicine and Jefferson Davis Hospital, Houston, Texas

The effects of 2'-hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-benzomorphan (Win 20,228) a weak narcotic antagonist, have been studied in man. In the treatment of postoperative pain 10-20 mg/70 kg of Win 20,228 produced analgesia equivalent to 10 mg/70 kg of morphine. The degree of respiratory depression produced by 20 mg/70 kg of Win 20,228 was comparable to that of 10 mg/70 kg of morphine. The subjective effects of Win 20,228 were qualitatively and quantitatively similar to those of morphine. Except for one patient who reported "crazy thoughts," nalorphine-like psychotomimetic effects were not observed in other patients or healthy subjects.

Win 20,228 was shown to be a weak antagonist of morphine induced respiratory depression and the respiratory depression of Win 20,228 was not antagonized by potent narcotic antagonists. In contrast to morphine, Win 20,228 in doses greater than 2 mg/kg intravenously produced tachycardia and hypertension. Win 20,228 may represent the first clinically useful potent analgesic with minimal addiction liability.

Submitted on May 20, 1963
Accepted on October 16, 1963




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
J. P. Zacny, J. L. Hill, M. L. Black, and P. Sadeghi
Comparing the Subjective, Psychomotor and Physiological Effects of Intravenous Pentazocine and Morphine in Normal Volunteers
J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1197 - 1207.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1964 by the American Society for Pharmacology and Experimental Therapeutics.